• Profile
Close

Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence

Head & Neck Jan 14, 2020

Ham JC, van Meerten E, Fiets WE, et al. - Given the limited progression-free survival (PFS) benefit of methotrexate in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), researchers examined if adding cetuximab to methotrexate enhances PFS. In the phase-Ib-study, patients with R/M SCCHN received methotrexate and cetuximab as first-line treatment or methotrexate alone (2:1). In the combination group, median PFS was 4.5 months vs 2.0 months in the methotrexate group. Outcomes revealed an increase in PFS in correlation with providing cetuximab with methotrexate in R/M SCCHN-patients; this improvement was observed without increased toxicity.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay